WO2024184796 - SUSTAINED RELEASE SOLID ORAL BOLUS
National phase entry:
Publication Number
WO/2024/184796
Publication Date
12.09.2024
International Application No.
PCT/IB2024/052090
International Filing Date
04.03.2024
Title **
[English]
SUSTAINED RELEASE SOLID ORAL BOLUS
[French]
BOLUS ORAL SOLIDE À LIBÉRATION PROLONGÉE
Applicants **
WELFARE CONCEPTS LIMITED
301r Botany Road
Golflands
Auckland, 2013, NZ
Inventors
ALAWI, Fadil
301r Botany Road
Golflands
Auckland, 2013, NZ
NANJAN, Karthigeyan
301r Botany Road
Golflands
Auckland, 2013, NZ
OLDE RIEKERINK, Richard Gerhardus Martinus
301r Botany Road
Golflands
Auckland, 2013, NZ
EMSLIE, Forbes Richard
301r Botany Road
Golflands
Auckland, 2013, NZ
Priority Data
2023900580
06.03.2023
AU
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP Australia
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2117 | |
| EPO | Filing, Examination | 15922 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 10435 |
Total: 29580 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A sustained release solid oral bolus that, once ingested, is capable of providing sustained release of a therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID), and its use for treating fever, pain and/or inflammation, preferably caused by periparturient disorders, such as mastitis, lameness, endometritis, metritis, or subfertility.[French]
L'invention concerne un bolus oral solide à libération prolongée qui, une fois ingéré, est capable de fournir une libération prolongée d'une quantité thérapeutiquement efficace d'un médicament anti-inflammatoire non stéroïdien (AINS), et son utilisation pour le traitement de la fièvre, de la douleur et/ou de l'inflammation, de préférence provoquées par des troubles périnataux, tels que la mastite, la boiterie, l'endométrite, la métrite ou l'hypofertilité.